Clinical Trial Update: Endostar for Locally Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Endostar in locally recurrent nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN